BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 20174566)

  • 1. Use of DNA-damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients.
    Walker LC; Thompson BA; Waddell N; ; Grimmond SM; Spurdle AB
    PLoS Genet; 2010 Feb; 6(2):e1000850. PubMed ID: 20174566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1 and BRCA2 missense variants of high and low clinical significance influence lymphoblastoid cell line post-irradiation gene expression.
    Waddell N; Ten Haaf A; Marsh A; Johnson J; Walker LC; ; Gongora M; Brown M; Grover P; Girolami M; Grimmond S; Chenevix-Trench G; Spurdle AB
    PLoS Genet; 2008 May; 4(5):e1000080. PubMed ID: 18497862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling.
    Larsen MJ; Kruse TA; Tan Q; Lænkholm AV; Bak M; Lykkesfeldt AE; Sørensen KP; Hansen TV; Ejlertsen B; Gerdes AM; Thomassen M
    PLoS One; 2013; 8(5):e64268. PubMed ID: 23704984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases.
    Colombo M; Giarola M; Mariani L; Ripamonti CB; De Benedetti V; Sardella M; Losa M; Manoukian S; Peissel B; Pierotti MA; Pilotti S; Radice P
    Mod Pathol; 2008 Oct; 21(10):1262-70. PubMed ID: 18327210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damage.
    Kote-Jarai Z; Matthews L; Osorio A; Shanley S; Giddings I; Moreews F; Locke I; Evans DG; Eccles D; ; Williams RD; Girolami M; Campbell C; Eeles R
    Clin Cancer Res; 2006 Jul; 12(13):3896-901. PubMed ID: 16818684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families.
    Larsen MJ; Thomassen M; Tan Q; Lænkholm AV; Bak M; Sørensen KP; Andersen MK; Kruse TA; Gerdes AM
    BMC Med Genomics; 2014 Jan; 7():9. PubMed ID: 24479546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
    Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
    Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
    Campos B; Díez O; Domènech M; Baena M; Balmaña J; Sanz J; Ramírez A; Alonso C; Baiget M
    Hum Mutat; 2003 Oct; 22(4):337. PubMed ID: 12955719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular classification of familial non-BRCA1/BRCA2 breast cancer.
    Hedenfalk I; Ringner M; Ben-Dor A; Yakhini Z; Chen Y; Chebil G; Ach R; Loman N; Olsson H; Meltzer P; Borg A; Trent J
    Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2532-7. PubMed ID: 12610208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
    Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
    Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional characteristics of familial non-BRCA1/BRCA2 breast tumors.
    Fernández-Ramires R; Gómez G; Muñoz-Repeto I; de Cecco L; Llort G; Cazorla A; Blanco I; Gariboldi M; Pierotti MA; Benítez J; Osorio A
    Int J Cancer; 2011 Jun; 128(11):2635-44. PubMed ID: 20715112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers.
    Yan M; Xu H; Waddell N; Shield-Artin K; Haviv I; ; McKay MJ; Fox SB
    Breast Cancer Res; 2012 Apr; 14(2):R69. PubMed ID: 22537934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA signatures in hereditary breast cancer.
    Murria Estal R; Palanca Suela S; de Juan Jiménez I; Egoavil Rojas C; García-Casado Z; Juan Fita MJ; Sánchez Heras AB; Segura Huerta A; Chirivella González I; Sánchez-Izquierdo D; Llop García M; Barragán González E; Bolufer Gilabert P
    Breast Cancer Res Treat; 2013 Nov; 142(1):19-30. PubMed ID: 24129975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
    Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
    Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil.
    Pessôa-Pereira D; Evangelista AF; Causin RL; da Costa Vieira RA; Abrahão-Machado LF; Santana IVV; da Silva VD; de Souza KCB; de Oliveira-Silva RJ; Fernandes GC; Reis RM; Palmero EI; Marques MMC
    BMC Cancer; 2020 Feb; 20(1):143. PubMed ID: 32087690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of molecular markers for BRCA1 and BRCA2 heterozygosity using gene expression profiling.
    Salmon AY; Salmon-Divon M; Zahavi T; Barash Y; Levy-Drummer RS; Jacob-Hirsch J; Peretz T
    Cancer Prev Res (Phila); 2013 Feb; 6(2):82-90. PubMed ID: 23341570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation.
    Alvarez S; Diaz-Uriarte R; Osorio A; Barroso A; Melchor L; Paz MF; Honrado E; Rodríguez R; Urioste M; Valle L; Díez O; Cigudosa JC; Dopazo J; Esteller M; Benitez J
    Clin Cancer Res; 2005 Feb; 11(3):1146-53. PubMed ID: 15709182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ionizing radiation or mitomycin-induced micronuclei in lymphocytes of BRCA1 or BRCA2 mutation carriers.
    Gutiérrez-Enríquez S; Ramón Y Cajal T; Alonso C; Corral A; Carrasco P; Cornet M; Sanz J; Ribas M; Baiget M; Diez O
    Breast Cancer Res Treat; 2011 Jun; 127(3):611-22. PubMed ID: 20625817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
    de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
    Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.